Experimental cancer drug tested in patients with no other options
NCT ID NCT04550897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called BM7PE immunotoxin in 14 people with colorectal cancer that had spread and was no longer responding to standard chemotherapy. The goal was to find a safe dose and see if it could help patients live longer. The study was stopped early, so we have limited information on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BM7PE immunotoxin
- What this could lead to
- If successful, this could offer a new treatment option for patients with advanced colorectal cancer who have run out of standard therapies.
- What could go wrong
- The trial was terminated early, so results are limited. It was a small, early-phase study, so safety and effectiveness are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oslo University Hospital
Oslo, Oslo, 0310, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a vaccine boost immunotherapy against a stubborn cancer?
- What does recovery really look like after aggressive peritoneal cancer surgery?
- Chemo holidays put to the test: can scheduled breaks beat continuous treatment for advanced colorectal cancer?
- Can two immune boosters outsmart Chemo-Resistant colon cancer?
- Could a liver transplant from a living donor help fight colorectal cancer that spread?